Eltoprazine (DB12883): A Comprehensive Report on a Multi-Target Serotonergic Agent's Pharmacological Profile, Clinical Development, and Troubled Trajectory

Executive Summary

Eltoprazine is a phenylpiperazine derivative with a complex and potentially valuable pharmacological profile, characterized primarily by its action as a partial agonist at serotonin 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor. Originally developed in the 1980s by Duphar and Solvay Pharmaceuticals as a "serenic" or anti-aggressive agent, its clinical journey has been marked by multiple strategic repositionings and significant corporate turmoil. Initial development for aggression was stymied by regulatory hurdles of the time, which viewed aggression as a symptom rather than a treatable disorder. Subsequently, the drug was explored for attention deficit hyperactivity disorder (ADHD) and cognitive impairment associated with schizophrenia (CIAS), with a Phase IIa trial in adult ADHD yielding positive results.

The most compelling application for Eltoprazine emerged in the treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease (PD). Based on a strong scientific rationale targeting the serotonergic "false transmitter" mechanism, Eltoprazine demonstrated robust efficacy in preclinical models and, critically, in a Phase I/IIa human proof-of-concept study. This trial showed that Eltoprazine could significantly reduce LID without compromising the primary motor benefits of Levodopa, a crucial finding that de-risked its clinical development. However, a pivotal Phase IIb study was halted not for scientific reasons, but due to the corporate collapse of its final developer, Amarantus BioScience. This report provides a comprehensive analysis of Eltoprazine's pharmacology, its multifaceted clinical development history across all indications, and a forensic examination of the corporate and regulatory factors that led to its abandonment. The evidence suggests that Eltoprazine is not a failed drug but rather an orphaned asset, whose promising potential in treating LID, ADHD, and aggression remains unfulfilled due to a confluence of corporate instability and an evolving regulatory landscape.

1. Introduction: The Serotonergic System and the Promise of Eltoprazine

1.1. Overview of Serotonin Receptors (5-HT1A, 5-HT1B, 5-HT2C) as Therapeutic Targets in CNS Disorders

The serotonin (5-hydroxytryptamine, 5-HT) system is a critical neuromodulatory network in the central nervous system (CNS) that influences a vast array of physiological and behavioral processes, including mood, anxiety, aggression, cognition, and motor control.[1] Its complexity is underscored by the existence of at least 14 distinct receptor subtypes, each with a unique distribution and signaling function.[3] Among these, the 5-HT1A, 5-HT1B, and 5-HT2C receptors have been extensively studied as targets for psychopharmacological intervention.

The 5-HT1A and 5-HT1B receptors frequently function as inhibitory autoreceptors. Presynaptic 5-HT1A receptors are located on the soma and dendrites of serotonin neurons in the raphe nuclei, while 5-HT1B receptors are primarily located on the presynaptic terminals. Activation of these autoreceptors by serotonin or agonist drugs leads to a decrease in serotonin synthesis and release, forming a negative feedback loop.[3] Postsynaptically, these receptors are widely distributed in brain regions like the hippocampus and cortex, where they mediate inhibitory neurotransmission.[3] This dual pre- and postsynaptic role makes them key targets for treating anxiety, depression, and, as has been discovered more recently, motor control disorders.[4]

In contrast, the 5-HT2C receptor is a G-protein coupled receptor that generally exerts an excitatory influence and is known to modulate the activity of other neurotransmitter systems, particularly dopamine and norepinephrine.[7] Antagonism at the 5-HT2C receptor can lead to an increase in the release of these catecholamines in brain regions such as the prefrontal cortex, a mechanism implicated in the therapeutic effects of some atypical antipsychotics and antidepressants.[8] The intricate interplay between these three receptor subtypes provides a rich substrate for developing drugs with complex, multi-faceted effects on CNS function.

1.2. Eltoprazine: A Phenylpiperazine Derivative with a Unique Multi-Receptor Profile

Eltoprazine, first described in the scientific literature in 1987 [10], is a small molecule belonging to the phenylpiperazine class of serotonergic agents.[7] It was originally developed by Duphar and subsequently Solvay Pharmaceuticals under the developmental code DU-28853.[10] Eltoprazine is chemically and pharmacologically related to other so-called "serenic" agents, such as fluprazine and batoprazine, which were investigated for their specific anti-aggressive properties.[10] What distinguishes Eltoprazine is its unique and balanced affinity for multiple serotonin receptors, acting as a partial agonist at both 5-HT1A and 5-HT1B receptors while simultaneously acting as an antagonist at the 5-HT2C receptor.[7] This multi-target profile suggested a potential to modulate several CNS pathways at once, forming the basis for its investigation across a wide spectrum of disorders, from pathological aggression to cognitive impairment and movement disorders.[10]

1.3. Physicochemical Properties and Formulations

Eltoprazine is an achiral small molecule that has been formulated for both preclinical and clinical research, most commonly as a hydrochloride salt for enhanced stability and solubility.

Chemical Structure and Formula: The base form of Eltoprazine has the chemical formula C12H16N2O2 and a molecular weight of 220.27 g/mol.[7] Its hydrochloride salt form (

C12H17ClN2O2) has a molecular weight of 256.73 g/mol, and a dihydrochloride salt (C12H18Cl2N2O2) with a molecular weight of 293.19 g/mol has also been described.[18]

Nomenclature and Identifiers: Eltoprazine is known by several names and identifiers across scientific and regulatory databases. Its systematic IUPAC name is 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine. It is frequently referred to by its developmental codes, DU-28853 and DU-28893.[7] Key database identifiers include CAS Number 98224-03-4 (for the base) and 98206-09-8 (for the hydrochloride salt), DrugBank ID DB12883, and FDA UNII 510M006KO6.[7]

Solubility and Formulation: For research purposes, Eltoprazine is soluble in dimethyl sulfoxide (DMSO) at concentrations of 10 mM or greater.[7] Various protocols for in vivo formulations have been established, often using co-solvents like polyethylene glycol 300 (PEG300), Tween-80, or sulfobutylether-beta-cyclodextrin (SBE-β-CD) to achieve clear solutions for administration.[16] In human clinical trials, Eltoprazine has been administered as oral capsules in various strengths, including 2.5 mg, 5 mg, and 7.5 mg.[12]

Table 1: Eltoprazine - Key Identifiers and Physicochemical Properties

| Property | Value | Source(s) |

| :--- | :--- | :--- |

| DrugBank ID | DB12883 | 12 |

| Type | Small Molecule | 12 |

| CAS Number (Base) | 98224-03-4 | 7 |

| CAS Number (HCl) | 98206-09-8 | 18 |

| IUPAC Name | 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine | 10 |

| Synonyms | DU-28853, DU-28893 | 7 |

| Molecular Formula (Base) | C12H16N2O2 | 7 |

| Molecular Weight (Base) | 220.27 g/mol | 7 |

2. Pharmacological Profile and Mechanism of Action

2.1. Multi-Receptor Binding Affinity: A 5-HT1A/1B Agonist and 5-HT2C Antagonist

The defining characteristic of Eltoprazine's pharmacology is its simultaneous interaction with three key serotonin receptor subtypes. It acts as a partial agonist at 5-HT1A and 5-HT1B receptors, while concurrently functioning as an antagonist at the 5-HT2C receptor.[7] This mixed agonist-antagonist profile is the foundation for its diverse behavioral effects. Receptor binding studies have quantified these interactions, revealing dissociation constants (

Ki) of 40 nM for the 5-HT1A receptor, 52 nM for the 5-HT1B receptor, and 81 nM for the 5-HT2C receptor.[7] Autoradiographic studies using radiolabeled Eltoprazine in rat brain tissue confirmed a high affinity for 5-HT1 sites, with an apparent dissociation constant (

Kd) of 11 nM.[11]

Table 2: Summary of Eltoprazine's Receptor Binding Profile

| :--- | :--- | :--- | :--- |

| 5-HT1A Receptor | Partial Agonist | Ki = 40 | 7 |

| 5-HT1B Receptor | Partial Agonist | Ki = 52 | 7 |

| 5-HT2C Receptor | Antagonist | Ki = 81 | 7 |

2.2. The "Serenic" Hypothesis: Preclinical Evidence for Anti-Aggressive Effects

Eltoprazine was originally conceived and developed as a "serenic," a class of compounds intended to specifically reduce pathological aggression without the generalized sedative effects of traditional tranquilizers or neuroleptics.[7] This concept was supported by extensive preclinical research. In animal models such as isolation-induced aggression in mice and resident-intruder aggression in rats, Eltoprazine demonstrated a potent and highly specific anti-aggressive effect.[11] The specificity of this effect was a key differentiator; unlike benzodiazepines, which can paradoxically increase aggression at low doses, or neuroleptics, which cause profound sedation, Eltoprazine inhibited offensive aggression while leaving social interaction and exploratory behaviors intact or even enhanced.[14] This unique behavioral profile, which did not diminish with subchronic treatment, suggested a novel mechanism for managing aggression that could preserve normal social functioning, making it a highly attractive clinical candidate for this indication.[14]

2.3. Modulation of Dopaminergic and Noradrenergic Systems in Key Brain Regions

The serotonergic activity of Eltoprazine produces significant downstream effects on catecholamine systems, which vary by brain region and help explain its potential utility across different CNS disorders. In vivo microdialysis studies in rats have shown that Eltoprazine administration leads to increased release of both dopamine (DA) and norepinephrine (NE) in the medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC).[8] This effect is consistent with its 5-HT2C antagonist properties, as 5-HT2C receptors typically exert a tonic inhibitory control over cortical catecholamine release. The elevation of DA and NE in these prefrontal regions is a pharmacological signature shared by effective treatments for ADHD, such as psychostimulants, providing a strong mechanistic rationale for investigating Eltoprazine in this disorder.[8]

In contrast, while Eltoprazine also increases DA concentration in the nucleus accumbens (NAc), a key reward center, it was found to have no effect on DA levels in the striatum.[3] This striatal-sparing effect is of paramount importance for its potential use in Parkinson's disease. It suggests that Eltoprazine can modulate the serotonergic system to control L-DOPA-induced dyskinesia without directly interfering with the striatal dopamine levels crucial for L-DOPA's primary therapeutic effect. Furthermore, Eltoprazine was observed to decrease 5-HT release in the mPFC and NAc, a finding consistent with its agonist activity at inhibitory presynaptic 5-HT1A/1B autoreceptors.[3]

2.4. Impact on Impulsivity, Anxiety, and Cognition in Preclinical Models

Preclinical studies have revealed a complex and nuanced behavioral profile for Eltoprazine beyond its anti-aggressive effects.

Impulsivity: Eltoprazine's effects on impulsivity are not uniform, supporting the hypothesis that different forms of impulsivity are governed by distinct neural circuits. In rat models, it was found to decrease "waiting" impulsivity (impulsive choice), a desirable therapeutic effect, while simultaneously increasing "stopping" impulsivity (impulsive action), which could be a limiting side effect.[3]
Anxiety: The preclinical data on anxiety are equivocal. In the elevated plus-maze test, Eltoprazine produced anxiogenic-like effects, reducing the time spent in open arms. However, in the context fear conditioning test, it demonstrated a clear anxiolytic effect.[16] This inconsistent profile across different anxiety models likely contributed to the eventual de-prioritization of anxiety as a primary clinical indication.
Cognition: Evidence for a pro-cognitive effect comes from studies in a Drosophila model of Fragile X Syndrome. In these experiments, treatment with Eltoprazine, acting as a 5-HT1A agonist, was shown to ameliorate deficits in synaptic transmission, correct mitochondrial dysfunction, and improve motor behavior.[33] These findings provided a rationale for its clinical investigation in cognitive impairment associated with schizophrenia (CIAS).

Table 3: Overview of Key Preclinical Studies of Eltoprazine

| :--- | :--- | :--- | :--- |

2.5. Pharmacokinetic Profile: Absorption, Distribution, and Half-life in Animal and Human Studies

Eltoprazine has been administered to over 680 human subjects across its development history and is described as having an uncomplicated pharmacokinetic profile.[6] In a study with healthy human volunteers, a single 30 mg oral dose resulted in a maximum plasma concentration (

Cmax) of 62.9 ng/mL and an area under the curve (AUC) of 746 ng·h/mL.[12] The elimination half-life (

T1/2) in humans was determined to be approximately 5.9 hours following a 30 mg oral dose and 9.3 hours after an 8 mg intravenous dose, indicating suitability for once or twice-daily dosing regimens.[12] In mice, the drug demonstrated satisfactory oral bioavailability of 55%.[35]

3. Clinical Development for Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease

The most promising clinical application for Eltoprazine emerged from its investigation as a treatment for Levodopa-Induced Dyskinesia (LID), a debilitating side effect of long-term dopamine replacement therapy in Parkinson's Disease (PD).

3.1. Rationale: Targeting the Serotonergic "False Transmitter" Hypothesis in LID

The scientific rationale for using Eltoprazine in LID is rooted in the "false transmitter" hypothesis of dyskinesia pathogenesis.[6] In the healthy brain, exogenous L-DOPA is primarily taken up by dopaminergic neurons, converted to dopamine, and released in a regulated, physiological manner. However, in the advanced PD brain, the progressive loss of these dopaminergic terminals leads to a compensatory mechanism where the relatively preserved serotonergic neurons take up L-DOPA.[6] These serotonin neurons convert L-DOPA to dopamine but lack the appropriate autoregulatory feedback mechanisms to control its release. Consequently, dopamine is released erratically and non-physiologically, acting as a "false neurotransmitter" that leads to the pulsatile, over-stimulation of postsynaptic dopamine receptors, which is believed to be a primary driver of dyskinetic movements.[6]

The therapeutic strategy, therefore, is to dampen the aberrant activity of these serotonin neurons. Eltoprazine's mechanism as a dual agonist at the inhibitory 5-HT1A (somatodendritic) and 5-HT1B (nerve terminal) autoreceptors makes it an ideal candidate to achieve this goal, theoretically reducing the erratic release of dopamine without directly affecting the dopaminergic system itself.[6]

3.2. Preclinical Efficacy in Rodent and Primate Models of LID

This strong scientific rationale was borne out in extensive preclinical testing. Eltoprazine was shown to be highly effective at suppressing LID in both 6-hydroxydopamine (6-OHDA)-lesioned rat models and in the gold-standard 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated non-human primate model of PD.[6] These studies confirmed that simultaneous activation of 5-HT1A and 5-HT1B receptors could almost completely eliminate dyskinesias.[37] However, these preclinical studies also raised a critical question for clinical development: in some animal models, the potent anti-dyskinetic effect was accompanied by a partial reduction in the therapeutic, anti-parkinsonian benefit of L-DOPA.[35] This suggested a potentially narrow therapeutic window, where the dose required to suppress dyskinesia might also dampen the desired motor improvements. A synergistic anti-dyskinetic effect was also observed when Eltoprazine was combined with amantadine, suggesting a possible combination therapy strategy to maximize efficacy while minimizing dose-related side effects.[35]

3.3. Phase I/IIa Dose-Finding Study (Svenningsson et al., 2015): A Detailed Analysis

Building on the robust preclinical data, a Phase I/IIa dose-finding study was conducted to assess Eltoprazine's efficacy and safety in human PD patients with LID. This trial represents the most significant clinical evidence for Eltoprazine's potential.

Study Design and Endpoints: The trial (NCT01257548; EudraCT 2009-015928-28) was a double-blind, randomized, placebo-controlled, crossover study involving 22 patients with PD and established LID.[6] Participants received single oral doses of Eltoprazine (2.5 mg, 5 mg, and 7.5 mg) or placebo, administered in combination with a challenge dose of L-DOPA. The primary efficacy endpoints were the change in dyskinesia severity, measured by the area under the curve (AUC) for the Clinical Dyskinesia Rating Scale (CDRS), and the change in parkinsonian motor symptoms, measured by the Unified Parkinson's Disease Rating Scale (UPDRS) Part III.[28]
Efficacy and Safety Results: The study successfully demonstrated a significant anti-dyskinetic effect. The 5 mg dose of Eltoprazine produced a statistically significant reduction in LID compared to placebo, as measured by the AUC for both the CDRS (p=0.004) and the Rush Dyskinesia Rating Scale (RDRS) (p=0.003).[6] A post-hoc analysis also confirmed an anti-dyskinetic effect for the 7.5 mg dose.[6] Most importantly, the study addressed the key concern from preclinical models. There was no statistically significant difference in UPDRS Part III motor scores between any Eltoprazine dose and placebo, demonstrating that the drug could reduce dyskinesia without compromising the essential anti-parkinsonian effect of L-DOPA at these doses.[6] The treatment was well-tolerated, with the most common adverse events being mild nausea and dizziness.[6]

Table 4: Detailed Results of the Phase I/IIa Study in PD-LID (Svenningsson et al., 2015)

| :--- | :--- | :--- | :--- | :--- | :--- |

| Change in CDRS AUC$_{0-3h}$ | -0.04 | -0.64 | -1.02 | -0.43 | 0.004 |

| Change in RDRS AUC$_{0-3h}$ | -0.05 | -0.02 | -0.15 | -0.03 | 0.003 |

| Change in Max CDRS Score | +0.71 | -0.82 | -1.14 | -0.61 | 0.005 |

| Change in UPDRS-III AUC$_{0-3h}$ | -0.57 | +0.49 | +0.35 | +0.45 | 0.988 (NS) |

Data derived from Svenningsson et al., Brain, 2015.6 NS = Not Significant.

3.4. The Stalled Phase IIb Study (NCT02439125): Design and Development Halt

Following the successful proof-of-concept study, a larger Phase IIb trial (NCT02439125) was initiated by Amarantus BioScience to confirm the findings with repeated dosing.[5] The study was designed as a multi-center, double-blind, placebo-controlled, four-way crossover trial intended to enroll 60 patients. Participants were to receive Eltoprazine HCl capsules (2.5 mg, 5 mg, or 7.5 mg) or placebo twice daily (BID) for three weeks.[5]

However, this pivotal follow-up study was never completed. In 2015, Amarantus announced it was pausing enrollment in the trial, citing "internal prioritization" of another asset (the Engineered Skin Substitute program) and a desire to evaluate an orphan drug designation pathway for Eltoprazine in PD-LID.[38] The halt was explicitly not due to any safety or efficacy concerns with Eltoprazine itself. As of the latest available information, the trial has no posted results, and its status remains unknown or not recently updated, effectively leaving the PD-LID program in limbo.[5]

3.5. Analysis: The Unfulfilled Potential of Eltoprazine in Parkinson's Disease

The clinical development pathway of Eltoprazine for LID serves as a clear example of a promising therapeutic candidate being successfully translated from a strong scientific hypothesis and robust preclinical data into compelling human proof-of-concept, only to be abandoned due to corporate and financial factors rather than scientific failure. The Phase I/IIa study by Svenningsson et al. was a model of translational science, directly testing and confirming the central hypothesis while simultaneously addressing the primary risk—potential worsening of motor function—that had been identified in animal models. The results clearly defined a therapeutic window, with the 5 mg dose providing significant anti-dyskinetic benefits without compromising L-DOPA's efficacy. The subsequent halt of the confirmatory Phase IIb trial represents a significant loss for the PD community, as a potentially valuable, non-dopaminergic treatment for a major unmet need was left undeveloped.

4. Clinical Investigations in Psychiatric and Behavioral Disorders

Prior to and concurrent with its investigation in Parkinson's Disease, Eltoprazine was evaluated in several psychiatric and behavioral indications, reflecting its broad serotonergic mechanism of action.

Table 5: Summary of Eltoprazine Clinical Trials Across All Indications

| :--- | :--- | :--- | :--- | :--- | :--- |

4.1. Aggression: The Original Indication and Its Regulatory Fate

Eltoprazine's journey began with its development as a "serenic" agent by Solvay and Duphar.[10] A large, multi-center, double-blind, placebo-controlled study was conducted in 160 mentally handicapped patients with aggressive behavior. Although the trial failed to meet its primary endpoint in the total sample, a post-hoc analysis suggested that Eltoprazine was significantly better than placebo at reducing aggression scores in a subgroup of the most severely aggressive patients.[63] Later, under Amarantus, a Phase II study in 29 elderly patients with Alzheimer's-related aggression also showed hints of efficacy, with a significant improvement on the Social Dysfunction and Aggression Scale (SDAS) in the most severely affected patients.[64]

Despite these signals of efficacy, the European Medicines Agency (EMA) denied marketing authorization for the aggression indication. The regulatory body's rationale was that aggression is a symptom, not a distinct, diagnosable disorder, and therefore not an approvable indication at the time.[10] This decision was a product of its era and highlights a significant historical challenge in psychopharmacology. The regulatory landscape has since evolved considerably. A prime example is the 2023 FDA approval of the atypical antipsychotic brexpiprazole (Rexulti) for the specific indication of "agitation associated with dementia due to Alzheimer's disease".[66] This landmark approval established that a well-defined, burdensome behavioral syndrome can be a valid therapeutic target, even if it cuts across traditional diagnostic boundaries. Eltoprazine's early failure was thus not necessarily a failure of the drug, but a failure to align with a regulatory paradigm that has now changed.

4.2. Cognitive Impairment Associated with Schizophrenia (CIAS)

The potential for Eltoprazine to treat cognitive deficits in schizophrenia was based on its mechanism of modulating prefrontal cortex activity via its serotonergic actions.[12] A Phase II trial, "Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults" (NCT01266174), was initiated to explore this hypothesis.[6] The study, sponsored by PsychoGenics and supported by the National Institute of Mental Health (NIMH), was completed.[55] However, despite its completion, no results from this trial appear to have been published in the peer-reviewed literature. This lack of published data for a completed trial is a significant information gap. While it could suggest neutral or negative findings, the subsequent financial collapse of the sponsoring companies means the data may have been left unanalyzed or unpublished, leaving the drug's potential in CIAS an open question.

4.3. Adult Attention Deficit Hyperactivity Disorder (ADHD)

Following its acquisition of the Eltoprazine program, PsychoGenics identified its potential for treating adult ADHD, leveraging the drug's unique behavioral signature and its ability to increase prefrontal catecholamine levels.[8] A Phase IIa double-blind, placebo-controlled, crossover study was conducted in adults with ADHD.[90]

The trial was successful, meeting its primary endpoint. Both the 5 mg and 10 mg doses of Eltoprazine demonstrated statistically significant superiority over placebo in reducing the total score on the ADHD Rating Scale-IV (ADHD-RS-IV) (p=0.003 for 5 mg; p=0.037 for 10 mg).[92] This effect was driven by significant improvements on the "Inattention" and "Hyperactivity" subscales. The drug was well-tolerated, with mild to moderate gastrointestinal issues and fatigue being the most common side effects.[90] These positive results for a non-stimulant therapy in a large and underserved market represented another promising clinical path for Eltoprazine that was ultimately not pursued due to the subsequent corporate failures.

5. The Corporate and Regulatory History of Eltoprazine

The trajectory of Eltoprazine is inextricably linked to the sequence of companies that stewarded its development, a journey characterized by strategic pivots and, ultimately, corporate collapse.

5.1. From Duphar/Solvay to PsychoGenics: A Shift in Therapeutic Focus

Eltoprazine's story began in the 1980s at Duphar, which was later part of Solvay Pharmaceuticals.[10] The initial focus was on its "serenic" properties, with the primary goal of developing a novel anti-aggression agent.[10] After conducting clinical trials in aggressive, mentally handicapped patients, the program faced a major setback with the EMA's refusal to grant marketing authorization, arguing that aggression was a symptom, not a disease.[10] Following Solvay's merger with Abbott Pharmaceuticals, the Eltoprazine program was out-licensed to PsychoGenics, a preclinical CRO specializing in CNS disorders.[13] Utilizing its proprietary in vivo behavioral screening platforms, PsychoGenics identified a new potential indication for Eltoprazine: adult ADHD.[90] This represented a critical strategic pivot, moving the asset from a challenging and ill-defined indication (aggression) to a well-established and commercially viable one (ADHD).

5.2. The Amarantus BioScience Era: A Promising Pipeline Asset Lost to Corporate Failure

PsychoGenics subsequently licensed Eltoprazine to Amarantus BioScience Holdings, Inc., a small biotechnology company.[13] Amarantus took over the development for PD-LID, adult ADHD, and Alzheimer's aggression, with the PD-LID program becoming the lead indication after the promising Phase I/IIa results.[13] However, Amarantus was a company with a broad and unfocused pipeline that included disparate assets such as an Engineered Skin Substitute (ESS) for severe burns, a neurotrophic factor (MANF), and various diagnostic tests (LymPro, MSPrecise).[38] This lack of strategic focus and the financial burden of multiple development programs likely contributed to its eventual downfall.

Table 6: Timeline of Eltoprazine's Corporate Development and Ownership

| :--- | :--- | :--- | :--- |

| ~2013–2017 | Amarantus BioScience | PD-LID, Adult ADHD, Alzheimer's Aggression | Licensed from PsychoGenics; Positive Phase I/IIa results in PD-LID; Phase IIb trial for PD-LID initiated and then halted. |

5.3. Analysis of the Development Halt: A Forensic Look at Corporate Instability and Financial Distress

The demise of the Eltoprazine program can be directly attributed to the corporate failure of Amarantus BioScience. The decision to halt the pivotal Phase IIb trial in PD-LID (NCT02439125) was a critical turning point. The company's stated reason was "internal prioritization" of its ESS program and the desire to explore an orphan drug pathway, not any safety or efficacy concerns with Eltoprazine itself.[38] This rationale, particularly the deprioritization of a Phase IIb-ready asset with strong human proof-of-concept, is a classic indicator of a company facing severe financial constraints and making difficult decisions about its limited resources.

The subsequent history of Amarantus confirms this assessment. The company ceased filing regular reports with the U.S. Securities and Exchange Commission (SEC) after 2017, leading to a securities registration termination.[101] Its stock (AMBS) was relegated to the OTC Pink "Expert Market," a tier for companies with limited public disclosure, and is now designated as "Dark or Defunct" with a stock price near zero.[106] Financial reports from its final years of operation showed significant net losses and mounting debt.[108] A flurry of press releases in its later years detailing acquisitions, divestitures, and a pivot toward the CBD wellness industry further paint a picture of a company struggling for a viable business model.[100] In 2018, Amarantus was delisted from the UN Global Compact due to a "failure to communicate progress".[114] Ultimately, the company became defunct, leaving Eltoprazine and its other assets in a state of legal and financial limbo.[112]

5.4. Lessons Learned from the Eltoprazine Development Saga

The story of Eltoprazine serves as a stark cautionary tale in drug development. It illustrates that promising science and positive clinical data are not, on their own, sufficient to bring a drug to market. The failure of Eltoprazine was not scientific but corporate. Its journey highlights the critical importance of strategic focus, adequate capitalization, and stable corporate stewardship. An asset with potential in multiple high-need indications was ultimately lost because it was passed between companies with shifting priorities and finally landed at a small, undercapitalized company that could not sustain its development.

6. Synthesis and Future Outlook

6.1. Eltoprazine's Legacy: A Potent Molecule Lost in Development Hell

Synthesizing the available evidence, Eltoprazine should not be categorized as a "failed drug" in the conventional sense of having been proven ineffective or unsafe. Rather, it is a promising clinical asset that has been orphaned by a series of corporate and regulatory misfortunes. Its development was halted at its most promising stage—immediately following positive Phase I/IIa proof-of-concept data in PD-LID—for reasons entirely unrelated to its clinical performance. The drug possesses a unique, multi-target serotonergic mechanism that has demonstrated clear therapeutic potential in preclinical models and early human trials for several significant CNS disorders.

6.2. Comparative Analysis: How Eltoprazine's Profile Stacks Up Against Other Serotonergic Agents and Current Treatments

Versus Other LID Treatments: The current therapeutic landscape for LID is limited. Amantadine is an established treatment, but its efficacy is modest and it carries its own side-effect profile.[47] The development pipeline for LID includes a variety of mechanisms, but few possess the specific, targeted serotonergic mechanism of Eltoprazine.[116] Eltoprazine's dual 5-HT1A/1B agonism, which preclinical studies suggest is synergistic for reducing LID, gives it a theoretical advantage over more selective single-target agents. The clinical data showing a reduction in dyskinesia without impairing motor function is a highly desirable profile.
Versus Other Aggression Treatments: The recent FDA approval of brexpiprazole for agitation in Alzheimer's has created a new regulatory and commercial precedent, validating the treatment of behavioral syndromes as a viable pathway.[66] Eltoprazine's "serenic" profile, characterized by a specific reduction in aggression without sedation, could offer a significant clinical advantage over antipsychotics, which often cause sedation, cognitive dulling, and motor side effects.

6.3. Recommendations for Future Research: Could Eltoprazine be Revived?

Despite its troubled history, the strong scientific and clinical foundation for Eltoprazine suggests that its revival could be a worthwhile endeavor for an appropriately resourced entity. The path forward would require a clear strategy:

Legal and IP Due Diligence: The first and most critical step is to conduct a thorough legal investigation to determine the current ownership status of the Eltoprazine intellectual property, currently entangled in the remnants of the defunct Amarantus BioScience.
Primary Indication Focus: The most de-risked and promising indication is PD-LID. A development program should restart with a well-funded Phase IIb trial that largely mirrors the design of the stalled NCT02439125, confirming the efficacy and safety of repeated dosing of the 5 mg and 7.5 mg doses.
Secondary Indication Strategy: The positive Phase IIa data in adult ADHD and the favorable shift in the regulatory landscape for behavioral symptoms make both ADHD and Alzheimer's-related agitation highly attractive secondary indications that could be pursued in parallel or sequentially.
Addressing Data Gaps: A key unanswered question is the outcome of the completed Phase II trial in CIAS (NCT01266174). An effort to recover and analyze this data from the trial sponsors or investigators would be highly valuable for understanding the drug's full cognitive profile.
Final Assessment: Eltoprazine represents a rare and compelling opportunity: a mid-stage clinical asset with a unique mechanism of action and positive human proof-of-concept data in multiple high-value indications. It is available not because of scientific failure, but because of corporate collapse. For a company with expertise in CNS drug development and the resources to navigate the legal and financial complexities of acquiring the asset, Eltoprazine holds significant, albeit dormant, potential to address major unmet medical needs.

Works cited

(PDF) Serotonin and Aggression - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/7918535_Serotonin_and_Aggression
The Impact of Serotonin and Dopamine on Human Aggression: A Systematic Review of the Literature - The Aquila Digital Community, accessed June 18, 2025, https://aquila.usm.edu/cgi/viewcontent.cgi?referer=&httpsredir=1&article=1011&context=masters_theses
Eltoprazine, a serotonin 1A/1B receptor agonist, resembles D-amphetamine on different measures of impulsivity - DSpace, accessed June 18, 2025, https://dspace.library.uu.nl/bitstream/1874/9146/10/c6.pdf
THE PSYCHOPHARMACOLOGY OF SEROTONIN, accessed June 18, 2025, https://www.psychiatry-psychopharmacology.com/Content/files/sayilar/117/3_1_1.pdf
Eltoprazine – Knowledge and References - Taylor & Francis, accessed June 18, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Eltoprazine/
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5014080/
CAS 98224-03-4 Eltoprazine - BOC Sciences, accessed June 18, 2025, https://www.bocsci.com/eltoprazine-cas-98224-03-4-item-157962.html
The 5-HT1A/1B-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and “waiting” impulsivity, but increases “stopping” impulsivity | Request PDF - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/310573053_The_5-HT1A1B-receptor_agonist_eltoprazine_increases_both_catecholamine_release_in_the_prefrontal_cortex_and_dopamine_release_in_the_nucleus_accumbens_and_decreases_motivation_for_reward_and_waiting_im
The 5-HT1A/1B-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and "waiting" impulsivity, but increases "stopping" impulsivity - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/27866999/
Eltoprazine - Wikipedia, accessed June 18, 2025, https://en.wikipedia.org/wiki/Eltoprazine
Eltoprazine, a drug which reduces aggressive behaviour, binds selectively to 5-HT1 receptor sites in the rat brain: an autoradiographic study - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/2340856/
ELTOPRAZINE - Inxight Drugs, accessed June 18, 2025, https://drugs.ncats.io/drug/510M006KO6
www.sec.gov, accessed June 18, 2025, https://www.sec.gov/Archives/edgar/data/1424812/000114420415043319/v415837_ex99-1.htm
Behavioural pharmacology of the serenic, eltoprazine - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/2091890/
Eltoprazine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/drugs/DB12883
Eltoprazine (DU 28853) | 5-HT Receptor Modulator | MedChemExpress, accessed June 18, 2025, https://www.medchemexpress.com/Eltoprazine.html
eltoprazine | C12H16N2O2 - ChemSpider, accessed June 18, 2025, https://www.chemspider.com/Chemical-Structure.59265.html
Eltoprazine hydrochloride | CAS 98224-03-4 | SCBT, accessed June 18, 2025, https://www.scbt.com/p/eltoprazine-hydrochloride-98224-03-4
Eltoprazine hydrochloride | 98206-09-8 | FE22657 - Biosynth, accessed June 18, 2025, https://www.biosynth.com/p/FE22657/98206-09-8-eltoprazine-hydrochloride
Eltoprazine dihydrochloride - TargetMol, accessed June 18, 2025, https://www.targetmol.com/compound/Eltoprazine%20dihydrochloride
Eltoprazine hydrochloride | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/salts/DBSALT002368
www.medchemexpress.com, accessed June 18, 2025, https://www.medchemexpress.com/Eltoprazine-hydrochloride.html#:~:text=Eltoprazine%20hydrochloride%20(Synonyms%3A%20DU%2028853%20hydrochloride)&text=Eltoprazine%20(DU%2028853)%20hydrochloride%20is,For%20research%20use%20only.
PRODUCT INFORMATION - Cayman Chemical, accessed June 18, 2025, https://caymanchem.com/pdfs/18428.pdf
Eltoprazine = 98 HPLC 98206-09-8 - Sigma-Aldrich, accessed June 18, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml1526
ELTOPRAZINE HYDROCHLORIDE - GSRS, accessed June 18, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5275JY4PKD
Eltoprazine (DU 28853) | CAS NO.:98224-03-4 - GlpBio, accessed June 18, 2025, https://www.glpbio.com/sp/eltoprazine-du-28853.html
CLINICAL TRIAL HIGHLIGHTS – DYSKINESIA - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6704371/
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/25669730/
Eltoprazine hydrochloride | CAS 98206-09-8 - Tocris Bioscience, accessed June 18, 2025, https://www.tocris.com/products/eltoprazine-hydrochloride_1860
ANIMAL MODELS OF AGGRESSION - ACNP, accessed June 18, 2025, https://acnp.org/wp-content/uploads/2017/11/c118_1699-1708.pdf
The 5-HT1A/1B-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in - Biopsychology, accessed June 18, 2025, https://www.bio.psy.ruhr-uni-bochum.de/bpsy/mam/content/papers/2017_korte_activationof5.pdf
Effect of eltoprazine (injected s.c. 1 h before the test) on anxiety in... - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/figure/Effect-of-eltoprazine-injected-sc-1-h-before-the-test-on-anxiety-in-elevated-plus_fig1_316278777
Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome - PMC - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11354613/
(PDF) Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/383124547_Activation_of_the_5-HT1A_Receptor_by_Eltoprazine_Restores_Mitochondrial_and_Motor_Deficits_in_a_Drosophila_Model_of_Fragile_X_Syndrome
Study of the Antidyskinetic Effect of Eltoprazine in Animal Models of Levodopa-Induced Dyskinesia. | Request PDF - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/235416262_Study_of_the_Antidyskinetic_Effect_of_Eltoprazine_in_Animal_Models_of_Levodopa-Induced_Dyskinesia
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/23389842/
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study - Oxford Academic, accessed June 18, 2025, https://academic.oup.com/brain/article/138/4/963/280283
Amarantus BioSciences, Inc. To Focus Near-Term Development Efforts On Engineered Skin Substitute For Indications In Rare Pediatric Diseases - BioSpace, accessed June 18, 2025, https://www.biospace.com/amarantus-biosciences-inc-to-focus-near-term-development-efforts-on-engineered-skin-substitute-for-indications-in-rare-pediatric-diseases
Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study - Oxford Academic, accessed June 18, 2025, https://academic.oup.com/brain/article-pdf/138/4/963/13798742/awu409.pdf
Eltoprazine for Treatment of Levodopa-induced Dyskinesias | Parkinson's Disease, accessed June 18, 2025, https://www.michaeljfox.org/grant/eltoprazine-treatment-levodopa-induced-dyskinesias
Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study - Neurobiology - Anders Björklund, accessed June 18, 2025, https://www.neurobiology.lu.se/sites/neurobiology.lu.se/files/publication_in_brain_a_journal_of_neurology.pdf
Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia - Journal of Movement Disorders, accessed June 18, 2025, https://www.e-jmd.org/journal/view.php?doi=10.14802/jmd.19029
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence - Frontiers, accessed June 18, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.805388/full
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? - Oxford Academic, accessed June 18, 2025, https://academic.oup.com/brain/article/138/4/829/279899
Pre-clinical characterization of 5-HT1A/1B receptor agonists for the treatment of L-DOPA-induced dyskinesia, accessed June 18, 2025, https://www.michaeljfox.org/grant/pre-clinical-characterization-5-ht1a1b-receptor-agonists-treatment-l-dopa-induced-dyskinesia
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia - Dove Medical Press, accessed June 18, 2025, https://www.dovepress.com/article/download/64344
Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management - PMC - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5586110/
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/26207892/
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/26639853/
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity | Request PDF - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/304833096_Eltoprazine_prevents_levodopa-induced_dyskinesias_by_reducing_striatal_glutamate_and_direct_pathway_activity
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?, accessed June 18, 2025, https://academic.oup.com/brain/article-pdf/138/4/829/11141269/awu407.pdf
5-HT1A Agonists and Dyskinesia in Parkinson's Disease: A Pharmacological Perspective, accessed June 18, 2025, https://www.tandfonline.com/doi/pdf/10.2217/nmt-2018-0017
Further pharmacological characterization of eltoprazine: Focus on its anxiolytic, anorexic, and adverse-effect potential - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/316278777_Further_pharmacological_characterization_of_eltoprazine_Focus_on_its_anxiolytic_anorexic_and_adverse-effect_potential
EU Clinical Trials Register, accessed June 18, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015928-28/SE
PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson's Patients, accessed June 18, 2025, https://www.psychogenics.com/wp-content/uploads/2020/06/Positive_Efficacy_Data_in_Levodopa_Induced_Dyskinesia.pdf
Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/272192029_Eltoprazine_counteracts_L-DOPA-induced_dyskinesias_in_Parkinson's_disease_a_dose-finding_study
Eltoprazine could tackle dyskinesia side effect in Parkinson's disease, study suggests, accessed June 18, 2025, https://pharmaceutical-journal.com/article/news/eltoprazine-could-tackle-dyskinesia-side-effect-in-parkinsons-disease-study-suggests
Parkinson's Disease Unknown Status Phase 2 Trials for Eltoprazine (DB12883) - DrugBank, accessed June 18, 2025, https://go.drugbank.com/indications/DBCOND0028039/clinical_trials/DB12883?phase=2&status=unknown_status
A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients - ClinicalTrials.Veeva, accessed June 18, 2025, https://ctv.veeva.com/study/a-study-of-efficacy-and-safety-of-eltoprazine-hcl-for-treating-levodopa-induced-dyskinesia-in-parkin
(PDF) CLINICAL TRIAL HIGHLIGHTS – JULY 2019 DYSKINESIA - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/334639273_CLINICAL_TRIAL_HIGHLIGHTS_-_JULY_2019_DYSKINESIA
Amarantus BioScience Holdings, Inc. - MedPath, accessed June 18, 2025, https://trial.medpath.com/organization/06e33d04892b40e5/amarantus-bioscience-holdings-inc
Possible Parkinson's Treatment for Levodopa-Induced Dyskinesia Gets US Patent Protection, accessed June 18, 2025, https://parkinsonsnewstoday.com/news/amarantus-gets-us-patent-covering-method-of-treating-parkinsons-disease-levodopa-induced-dyskinesia/
a double-blind, placebo- and baseline-controlled multi-centre study. The Eltoprazine Aggression Research Group - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/7814828/
AMBS: Amarantus Announces Positive Phase II Data for Eltoprazine in Alzheimer's Aggression - Zacks Small Cap Research, accessed June 18, 2025, https://scr.zacks.com/news/news-details/2015/AMBS-Amarantus-Announces-Positive-Phase-II-Data-for-Eltoprazine-in-Alzheimers-Aggression/default.aspx
SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Positive Phase II Data for Eltoprazine - ACCESS Newswire, accessed June 18, 2025, https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/seethruequity-issues-update-on-amarantus-bioscience-holdings-inc.-otc-434754
FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease, accessed June 18, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease
Brexpiprazole for the Treatment of Agitation in Alzheimer's Disease Dementia: Clinical Uncertainties and the Path Forward - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/39648108/
FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease, accessed June 18, 2025, https://www.psychiatryonline.org/doi/10.1176/appi.pn.2023.07.7.17
Alzheimer's Association Statement on FDA Approval of Brexpiprazole, accessed June 18, 2025, https://www.alz.org/news/2023/alzheimer-s-association-statement-on-fda-approval-of-brexpiprazole
And now, the FDA approves a medication for behavioral symptoms of Alzheimer's disease, accessed June 18, 2025, https://mind.uci.edu/and-now-the-fda-approves-a-medication-for-behavioral-symptoms-of-alzheimers-disease/
Full article: A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease, accessed June 18, 2025, https://www.tandfonline.com/doi/full/10.1080/14737175.2024.2407836
Brexpiprazole: A new option in treating agitation in Alzheimer's dementia—Insights from transgenic mouse models, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11544443/
FDA Approves First Treatment for Alzheimer's-Associated Agitation - BrightFocus, accessed June 18, 2025, https://www.brightfocus.org/es/news/fda-approves-first-treatment-for-alzheimers-associated-agitation/
Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti - Medical News Today, accessed June 18, 2025, https://www.medicalnewstoday.com/articles/fda-fast-tracks-brexpiprazole-for-dementia-what-you-need-to-know
Depressive Disorder Drug Promising for Alzheimer's Disease Agitation - MedCentral, accessed June 18, 2025, https://www.medcentral.com/neurology/dementia/depressive-disorder-drug-promising-for-alzheimers-disease-agitation
New Alzheimer's Disease Drugs Receive FDA Approval, Offering Hope - Baystate Health, accessed June 18, 2025, https://www.baystatehealth.org/articles/new-alzheimers-disease-drugs
FDA Approves First Treatment for Agitation Associated With Alzheimer Disease Dementia, accessed June 18, 2025, https://www.psychiatrictimes.com/view/fda-approves-first-treatment-for-agitation-associated-with-alzheimer-disease-dementia
FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients, accessed June 18, 2025, https://www.clinicallab.com/fda-approves-first-drug-to-treat-dementia-associated-agitation-in-ad-patients-27239
Pharmacological Advances in the Treatment of Schizophrenia - Psychiatry Online, accessed June 18, 2025, https://psychiatryonline.org/doi/pdf/10.1176/appi.ajp-rj.2016.110102
Clinical Study: Drug Targeting Serotonin May Help Stop Dyskinesia | Parkinson's Disease, accessed June 18, 2025, https://www.michaeljfox.org/news/clinical-study-drug-targeting-serotonin-may-help-stop-dyskinesia
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults - ClinicalTrials.Veeva, accessed June 18, 2025, https://ctv.veeva.com/study/effects-of-eltoprazine-on-cognitive-impairment-associated-with-schizophrenia-cias-in-adults
Pharmacological Advances in the Treatment of Schizophrenia - Psychiatry Online, accessed June 18, 2025, https://psychiatryonline.org/doi/10.1176/appi.ajp-rj.2016.110102
Eltoprazine Completed Phase 2 Trials for Cognitive Impairment (CI) / Schizophrenia Treatment | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/drugs/DB12883/clinical_trials?conditions=DBCOND0138824%2CDBCOND0018504&phase=2&purpose=treatment&status=completed
INTO THE PIPELINE: THE LATEST IN PSYCHOPHARMACOLOGY, accessed June 18, 2025, https://cdn.neiglobal.com/content/congress/2020/pdf-slides/S14-pipeline-syl.pdf
Schizophrenia (DBCOND0018504) | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/conditions/DBCOND0018504
Cognitive Impairment Associated with Schizophrenia: A Review of the Humanistic Burden, accessed June 18, 2025, https://www.researchgate.net/publication/221848546_Cognitive_Impairment_Associated_with_Schizophrenia_A_Review_of_the_Humanistic_Burden
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/39144119
Clinical studies of interventions for cognitive impairment associated with schizophrenia (CIAS) (continued) - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/figure/Clinical-studies-of-interventions-for-cognitive-impairment-associated-with-schizophrenia_tbl2_365119345
Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11352256/
For Immediate Release PsychoGenics Announces Positive Phase-IIa for its First-in-Class Partial 5-HT1A – 5-HT1B Receptor Agoni, accessed June 18, 2025, https://www.psychogenics.com/wp-content/uploads/2020/06/Psychogenics-Eltoprazine-Press-Release-_Jun-08_.pdf
Product Update | Journal of Psychosocial Nursing and Mental Health Services, accessed June 18, 2025, https://journals.healio.com/doi/10.3928/02793695-20140225-89
Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD, accessed June 18, 2025, https://www.prnewswire.com/news-releases/amarantus-announces-positive-phase-2a-data-for-eltoprazine-in-adult-adhd-243482091.html
Serotonin: A never-ending story, accessed June 18, 2025, https://eclass.uoa.gr/modules/document/file.php/MED1200/%CE%A7.%20%CE%94%CE%91%CE%9B%CE%9B%CE%91/1-s2.0-S0014299914007389-main.pdf
New hope for burn patients - Drug Discovery News, accessed June 18, 2025, https://www.drugdiscoverynews.com/new-hope-for-burn-patients-9778
Amarantus BioSciences, Inc. Shareholders Approve All Matters Voted Upon At Annual Shareholders Meeting - BioSpace, accessed June 18, 2025, https://www.biospace.com/amarantus-biosciences-inc-shareholders-approve-all-matters-voted-upon-at-annual-shareholders-meeting
Amarantus creates spinouts in restructuring - BioPharma Dive, accessed June 18, 2025, https://www.biopharmadive.com/news/amarantus-creates-spinouts-in-restructuring/440629/
Amarantus BioSciences, Inc. Announces Acquisition Of Specialized Neuro-Diagnostics Company, DioGenix - BioSpace, accessed June 18, 2025, https://www.biospace.com/amarantus-biosciences-inc-announces-acquisition-of-specialized-neuro-diagnostics-company-diogenix
Amarantus Completes Acquisition of ESS from Lonza - SEC.gov, accessed June 18, 2025, https://www.sec.gov/Archives/edgar/data/1424812/000114420415042584/v415358_ex99-2.htm
Amarantus Completes Acquisition of ESS From Lonza - Contract Pharma, accessed June 18, 2025, https://www.contractpharma.com/breaking-news/amarantus-completes-acquisition-of-ess-from-lonza/
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products - Drug Development and Delivery, accessed June 18, 2025, https://drug-dev.com/amarantus-enters-into-agreement-to-license-diverse-therapeutics-portfolio-to-cbd-focused-emerald-organic-products/
SEC filings of Amarantus Bioscience Holdings Inc (AMBS) - AlphaResearch, accessed June 18, 2025, https://alpharesearch.io/sec-filings/AMBS/all-filings
EDGAR filings - SEC.gov, accessed June 18, 2025, https://www.sec.gov/edgar/browse/?CIK=0001424812
EDGAR Filing Documents for 0001144204-15-013699 - SEC.gov, accessed June 18, 2025, https://www.sec.gov/Archives/edgar/data/1424812/0001144204-15-013699-index.htm
schedule 13d - SEC.gov, accessed June 18, 2025, https://www.sec.gov/Archives/edgar/data/1424812/000175392622000541/g082973_13d.htm
Washington, DC 20549 - SEC.gov, accessed June 18, 2025, https://www.sec.gov/Archives/edgar/data/1424812/000114420415009154/v401763_8k.htm
AMBS - Amarantus Bioscience Holdings, Inc. | Company Profile - OTC Markets, accessed June 18, 2025, https://www.otcmarkets.com/stock/AMBS/profile
AMBS - Amarantus Bioscience Holdings, Inc. | Overview - OTC Markets, accessed June 18, 2025, https://www.otcmarkets.com/stock/AMBS
Total Receivables - Amarantus Bioscience Holdings Inc (OTC:AMBS) - Alpha Spread, accessed June 18, 2025, https://www.alphaspread.com/security/otc/ambs/financials/balance-sheet/total-receivables
Amarantus BioScience Holdings 2025 Company Profile - PitchBook, accessed June 18, 2025, https://pitchbook.com/profiles/company/52978-51
Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results - PR Newswire, accessed June 18, 2025, http://www.prnewswire.com/news-releases/amarantus-completes-sale-of-diagnostics-division-announces-fiscal-year-2015-and-first-quarter-2016-financial-results-581766011.html
Amarantus Releases Letter to Shareholders - GlobeNewswire, accessed June 18, 2025, https://www.globenewswire.com/news-release/2020/02/04/1979591/0/en/Amarantus-Releases-Letter-to-Shareholders.html
Amarantus Bioscience - 2025 Company Profile, Funding & Competitors - Tracxn, accessed June 18, 2025, https://tracxn.com/d/companies/amarantus-bioscience/__DkCmC0qssoorjrvXbvtvxrIv-KSQWjYiUBq5a_9_RZY
Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities - BioSpace, accessed June 18, 2025, https://www.biospace.com/amarantus-signs-non-binding-term-sheet-to-divest-cutanogen-corporation-in-exchange-for-the-extinguishment-of-potential-21m-in-liabilities
Amarantus BioScience Holdings, Inc. | UN Global Compact, accessed June 18, 2025, https://unglobalcompact.org/what-is-gc/participants/64141-Amarantus-BioScience-Holdings-Inc-
Amarantus Bioscience Holdings Inc. - BioCentury Company Profiles - BCIQ, accessed June 18, 2025, https://profiles.biocentury.com/companies/amarantus_bioscience_holdings_inc
Dyskinesia Pipeline Insight - DelveInsight, accessed June 18, 2025, https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight
(PDF) Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/376188520_Novel_Pharmacotherapies_for_L-DOPA-Induced_Dyskinesia
Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia | Request PDF - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/355362183_Novel_Pharmacotherapies_for_L-DOPA-Induced_Dyskinesia
Watch Out for Most Promising Therapies in Pipeline for PD-LID Treatment - DelveInsight, accessed June 18, 2025, https://www.delveinsight.com/blog/emerging-therapies-for-pd-lid-treatment
Q1.2025 Interim report January – March 2024 - Irlab, accessed June 18, 2025, https://irlab.se/wp-content/uploads/2025/05/IRLAB-Q1-FINAL-EN.pdf
IRLAB Publishes Interim Report for the Period January - March 2025 - FirstWord Pharma, accessed June 18, 2025, https://firstwordpharma.com/story/5957423
Dyskinesia- Pipeline Insight, 2025 - MarketResearch.com, accessed June 18, 2025, https://www.marketresearch.com/DelveInsight-v4028/Dyskinesia-Pipeline-Insight-40934044/
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease - BioSpace, accessed June 18, 2025, https://www.biospace.com/press-releases/strong-proof-of-concept-data-from-phase-2-trial-of-pde10a-inhibitor-cpl36-a-novel-once-daily-treatment-of-levodopa-induced-dyskinesia-in-parkinsons-disease
Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2025 - Research and Markets, accessed June 18, 2025, https://www.researchandmarkets.com/reports/4989066/levodopa-induced-dyskinesia-lid-pipeline
Celon Pharma Announces Positive Phase 2 Results for CPL'36 in Treating Levodopa-Induced Dyskinesia in Parkinson's Disease - BioPharma BoardRoom, accessed June 18, 2025, https://biopharmaboardroom.com/news/15/3018/celon-pharma-announces-positive-phase-2-results-for-cpl36-in-treating-levodopa-induced-dyskinesia-in-parkinsons-disease.html
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies - PMC - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9736114/
7 Most Promising Drugs in Parkinson's Disease Treatment Pipeline - BioSpace, accessed June 18, 2025, https://www.biospace.com/press-releases/7-most-promising-drugs-in-parkinsons-disease-treatment-pipeline
World-leader in drug development in Parkinson's: Reducing the burden and transforming lives - Irlab, accessed June 18, 2025, https://irlab.se/wp-content/uploads/2024/10/IRLAB-Q2-2024-presentation.pdf
Parkinson's Disease Levodopa-Induced Dyskinesia Market Size - DelveInsight, accessed June 18, 2025, https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market
New Levodopa Infusion Systems for Advanced Parkinson's Disease - touchNEUROLOGY, accessed June 18, 2025, https://touchneurology.com/wp-content/uploads/sites/3/2024/01/5.-touchNEURO-D-23-00027-Review-Antonini-23-26-1.pdf
Some Novel Therapies in Parkinson's Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature - MDPI, accessed June 18, 2025, https://www.mdpi.com/2227-9059/12/3/549
Translational profiling reveals novel gene expression changes in the direct and indirect pathways in a mouse model of levodopa induced dyskinesia - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11936753/
Multimodal Neuroimaging Reveals Distinct Characteristics of Levodopa-Induced Dyskinesias in de novo Parkinson's Disease Patients - bioRxiv, accessed June 18, 2025, https://www.biorxiv.org/content/10.1101/2025.01.20.633873v1.full.pdf
Editor's Pick: Novel Therapies and Targets for Parkinson's Disease - EMJ, accessed June 18, 2025, https://www.emjreviews.com/neurology/article/novel-therapies-and-targets-for-parkinsons-disease-j310125/
New Parkinson's Disease Treatments in the Clinical Trial Pipeline, accessed June 18, 2025, https://www.apdaparkinson.org/article/new-pd-treatments-clinical-trial-pipeline/
Monthly Research Review – January 2025 - The Science of Parkinson's, accessed June 18, 2025, https://scienceofparkinsons.com/2025/01/31/jan25/
Drug candidates with blockbuster potential for CNS diseases - Drug Target Review, accessed June 18, 2025, https://www.drugtargetreview.com/article/153045/drug-candidates-with-blockbuster-potential-for-cns-diseases/
Genetic therapies for movement disorders - current status - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11846774/
A New Extended-Release Levodopa Formulation - Davis Phinney Foundation, accessed June 18, 2025, https://davisphinneyfoundation.org/new-extended-release-levodopa-formulation-2024/
Some Novel Therapies in Parkinson's Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature - PMC - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10967979/
(PDF) Some Novel Therapies in Parkinson's Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/378625662_Some_Novel_Therapies_in_Parkinson's_Disease_A_Promising_Path_Forward_or_Not_Yet_A_Systematic_Review_of_the_Literature
Brain study challenges long-held views about Parkinson's movement disorders, accessed June 18, 2025, https://www.sciencedaily.com/releases/2025/01/250103124920.htm
The Evolving Landscape of Gene and Cell Therapies in Parkinson Disease: Pipeline Highlights - CGTLive®, accessed June 18, 2025, https://www.cgtlive.com/view/evolving-landscape-gene-cell-therapies-parkinson-disease
L-DOPA induces spatially discrete changes in gene expression in the forebrain of mice with a progressive loss of dopaminergic ne - bioRxiv, accessed June 18, 2025, https://www.biorxiv.org/content/biorxiv/early/2025/02/17/2025.02.13.638140.full.pdf

AI-Powered Research

Premium Access

Eltoprazine Advanced Drug Monograph

Generic Name

Drug Type

Chemical Formula

CAS Number

Eltoprazine (DB12883): A Comprehensive Report on a Multi-Target Serotonergic Agent's Pharmacological Profile, Clinical Development, and Troubled Trajectory

Executive Summary

1. Introduction: The Serotonergic System and the Promise of Eltoprazine

1.1. Overview of Serotonin Receptors (5-HT1A, 5-HT1B, 5-HT2C) as Therapeutic Targets in CNS Disorders

1.2. Eltoprazine: A Phenylpiperazine Derivative with a Unique Multi-Receptor Profile

1.3. Physicochemical Properties and Formulations

2. Pharmacological Profile and Mechanism of Action

2.1. Multi-Receptor Binding Affinity: A 5-HT1A/1B Agonist and 5-HT2C Antagonist

2.2. The "Serenic" Hypothesis: Preclinical Evidence for Anti-Aggressive Effects

2.3. Modulation of Dopaminergic and Noradrenergic Systems in Key Brain Regions

2.4. Impact on Impulsivity, Anxiety, and Cognition in Preclinical Models

2.5. Pharmacokinetic Profile: Absorption, Distribution, and Half-life in Animal and Human Studies

3. Clinical Development for Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease

3.1. Rationale: Targeting the Serotonergic "False Transmitter" Hypothesis in LID

3.2. Preclinical Efficacy in Rodent and Primate Models of LID

3.3. Phase I/IIa Dose-Finding Study (Svenningsson et al., 2015): A Detailed Analysis

3.4. The Stalled Phase IIb Study (NCT02439125): Design and Development Halt

3.5. Analysis: The Unfulfilled Potential of Eltoprazine in Parkinson's Disease

4. Clinical Investigations in Psychiatric and Behavioral Disorders

4.1. Aggression: The Original Indication and Its Regulatory Fate

4.2. Cognitive Impairment Associated with Schizophrenia (CIAS)

4.3. Adult Attention Deficit Hyperactivity Disorder (ADHD)

5. The Corporate and Regulatory History of Eltoprazine

5.1. From Duphar/Solvay to PsychoGenics: A Shift in Therapeutic Focus

5.2. The Amarantus BioScience Era: A Promising Pipeline Asset Lost to Corporate Failure

5.3. Analysis of the Development Halt: A Forensic Look at Corporate Instability and Financial Distress

5.4. Lessons Learned from the Eltoprazine Development Saga

6. Synthesis and Future Outlook

6.1. Eltoprazine's Legacy: A Potent Molecule Lost in Development Hell

6.2. Comparative Analysis: How Eltoprazine's Profile Stacks Up Against Other Serotonergic Agents and Current Treatments

6.3. Recommendations for Future Research: Could Eltoprazine be Revived?

Works cited

MedPath

Product

Company

Legal